In an unscientific poll, we asked respondents on ACC.org and Twitter about their use of high-sensitivity troponin (hsTn). Of the 234 respondents (136 from ACC.org and 98 from Twitter), 64% said they were routinely using hsTn in practice. The rest said they were not routinely using hsTn, with 24% working on a plan to start and the remaining 13% without a plan. Results based on the 2 polls were relatively similar for those currently using hsTn (60% vs. 68%). There were, however, differences among those who are not currently using hsTn. On ACC.org, 23% said they are working on a plan; on Twitter only 7% said they have plan in progress. On ACC.org, 17% said they have no plan; on Twitter, the number was 25%.

It is expected that the next 1-2 years there will be a complete change to high-sensitivity assays as manufacturer's cease production of conventional assays.

Clinical Topics: Acute Coronary Syndromes

Keywords: Troponin, Biological Assay

< Back to Listings